1. Home
  2. JHG vs BLCO Comparison

JHG vs BLCO Comparison

Compare JHG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janus Henderson Group plc

JHG

Janus Henderson Group plc

HOLD

Current Price

$47.84

Market Cap

6.8B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.27

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JHG
BLCO
Founded
1934
1853
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Investment Managers
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
JHG
BLCO
Price
$47.84
$17.27
Analyst Decision
Hold
Hold
Analyst Count
8
14
Target Price
$47.38
$17.31
AVG Volume (30 Days)
2.3M
330.3K
Earning Date
01-30-2026
02-18-2026
Dividend Yield
3.35%
N/A
EPS Growth
33.81
N/A
EPS
3.39
N/A
Revenue
$2,663,300,000.00
$4,976,000,000.00
Revenue This Year
$0.88
$8.06
Revenue Next Year
$8.74
$5.79
P/E Ratio
$14.08
N/A
Revenue Growth
14.14
6.23
52 Week Low
$28.26
$10.45
52 Week High
$49.42
$18.14

Technical Indicators

Market Signals
Indicator
JHG
BLCO
Relative Strength Index (RSI) 64.41 55.31
Support Level $47.56 $16.85
Resistance Level $48.24 $17.50
Average True Range (ATR) 0.27 0.43
MACD -0.14 -0.04
Stochastic Oscillator 44.60 64.02

Price Performance

Historical Comparison
JHG
BLCO

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: